Table 2 Crude and adjusted hazard ratio (HR) and 95% confidence interval (CI) for factors related to P. vivax reappearance
Variables | Reappearance N (%) | Crude HR (95% CI) | Adjusted HR* (95% CI) |
|---|---|---|---|
Treatment group | Â | Â | Â |
   DOT | 3 (2.8) | 1 | 1 |
   SAT | 12 (11.2) | 3.98 (1.12-14.09) | 6.21 (1.39-27.79) |
Age group | Â | Â | Â |
   3-7 years | 6 (11.1) | 1 | 1 |
   8-13 years | 1 (2.6) | 0.21 (0.03-1.72) | 0.02 (0.0008-0.54) |
   ≥14 years | 8 (6.5) | 0.60 (0.21-1.72) | 0.62 (0.17-2.32) |
Duration of fever pre-treatment | Â | Â | Â |
   0-2 days | 11 (9.8) | 1 | 1 |
   3+ days | 4 (3.9) | 0.38 (0.12-1.21) | 0.16 (0.04-0.68) |
Total primaquine dose/body weight | Â | Â | Â |
   ≥ 2.75 mg/kg | 13 (6.1) | 1 | 1 |
   < 2.75 mg/kg | 2 (50.0) | 8.39 (1.89-37.22) | 10.45 (2.02-54.03) |
Parasite count at Day0 | Â | Â | Â |
   < 10000 /µl | 8 (4.3) | 1 | 1 |
   ≥ 10000 /µl | 6 (20.0) | 4.87 (1.69-14.04) | 5.43 (1.59-18.54) |
Multiplicity of P. vivax genotype infection | 8 (4.7) | 1 | 1 |
   Single | 6 (15.8) | 5.97 (2.07-17.23) | 4.81 (1.53-15.16) |
   Multiple |  |  |  |
P. falciparum infection post-treatment for P. vivax | Â | Â | Â |
   No | 13 (6.3) | 1 | 1 |
   Yes | 2 (22.2) | 4.01 (0.90-17.77) | 13.66 (1.36-137.64) |
Gender | Â | Â | Â |
   Male | 10 (7.7) | 1 | - |
   Female | 5 (5.8) | 0.78 (0.27-2.28) |  |
Presence of gametocyte | Â | Â | Â |
   No | 10 (7.5) | 1 | - |
   Yes | 4 (4.9) | 0.63 (0.19-2.01) |  |
pvcs gene genotype | Â | Â | Â |
   VK210 | 12 (6.7) | 1 | - |
   VK247 | 1 (6.3) | 1.10 (0.14-8.49) |  |
   VK210&VK247 | 1 (7.1) | 1.06 (0.14-8.13) |  |
G6PD mutation status | Â | Â | Â |
   Wild-type | 12 (7.3) | 1 | - |
   G6PD Mahidol Homozygote | 0 | - |  |
   G6PD Mahidol Hemizygote | 2 (10.0) | 1.33 (0.30-5.93) |  |
   G6PD Mahidol Heterozygote | 1 (4.3) | 0.62 (0.081-4.78) |  |